medwireNews

Read more on this decision here

Click through for more information on this update

Use of SGLT2 inhibitors rather than sulfonylureas as an addition to metformin therapy may be associated with a reduced mortality risk for people with type 2 diabetes, suggest real-world study findings.

The addition of ipilimumab to nivolumab does not improve the survival outcomes of patients with advanced squamous non-small-cell cancer who have previously received chemotherapy, shows the phase 3 LUNG-MAP S1400I trial.

People with giant cell arteritis have an elevated risk for all-cause mortality relative to the general population, particularly within the first year following diagnosis, researchers report.

Study results suggest that individuals with type 2 diabetes and elevated insulin resistance are at greater risk for heart failure or death than those with greater insulin sensitivity.